FY2022 preliminary and unaudited results in line with guidance and FY2023 financial guidance introduced
COMPANY ANNOUNCEMENT NO. 1-2023
18 January 2023, Copenhagen, Denmark
Today we are pleased to announce that our full year 2022 preliminary and unaudited results are in line with guidance. In addition, financial guidance for 2023 is introduced.
Preliminary and unaudited key figures for Q4 and FY2022
| Mining | Cement | Non-Core Activities | Consolidated Group | |||||
| Q4 2022 | FY 2022 | Q4 2022 | FY 2022 | Q4 2022 | FY 2022 | Q4 2022 | FY 2022 | |
| Revenue, DKKbn | 4.4 | 15.1 (14.5-15.0) | 1.6 | 6.3 (6.0-6.5) | 0.5 | 0.5 (~0.5) | 6.5 | 21.8 (21.0-22.0) |
| Adj. EBITA margin | 12.4% | 10.6% (10.0-10.5%) | 3.2%* | 6.4%* (~6%) | ||||
| EBITA margin | 7.7% | 7.6% (~7.5%) | 4.3% | 3.3% (~3%) | Loss of DKK 0.4bn | Loss of DKK 0.4bn (loss of ~0.4bn) | 0% | 4.3% (~4%) |
Note: Numbers in brackets represent latest FY2022 guidance
* Consolidated Group adj. EBITA margin is not adjusted for the loss in Non-Core Activities
The Q4 and full year 2022 results include costs related to the thyssenkrupp Mining acquisition of DKK 125m and DKK 252m, respectively. In addition, the Q4 and full year 2022 results include costs related to wind-down of Russian activities of DKK 80m and DKK 200m, respectively.
FLSmidth will, as previously communicated, release the detailed and audited financial results for the full year of 2022 on 22 February 2023.
Financial guidance for FY2023
Guidance for full year 2023 reflects continued improvement of the underlying legacy Mining business, integration of TK Mining and the establishment of the Non-Core Activities segment.
| Guidance 2023 | Mining | Cement | Non-Core Activities | Consolidated Group |
| Revenue, DKKbn | 16.0-17.0 | 6.0-6.5 | 0.8-1.0 | 23.0-24.5 |
| Adj. EBITA margin | 9-10% | 6-7%* | ||
| EBITA margin | 4-5% | Loss of ~DKK 250-350m | 4-5% |
* Consolidated Group adj. EBITA margin is not adjusted for the loss in Non-Core Activities
Mining
The long-term outlook for the mining industry remains positive driven by strong industry fundamentals. Following a strong 2022, we expect market growth in 2023 to remain largely stable versus 2022. The former TK Mining business is expected to contribute with less than DKK 3bn in revenue in 2023 and is expected to have a dilutive effect on the full year 2023 adjusted Mining EBITA margin of around 2%-point. Guidance for Adjusted EBITA margin includes adjustments for integration costs of around DKK 550m for the full year 2023.
Cement
Short-term outlook for the cement industry remains impacted by overcapacity and the potential recession is expected to impact market demand negatively over the coming period.
Non-Core Activities
Non-Core Activities EBITA margin guidance for 2023 reflects the operationally loss-making nature of the business as well as costs related to contract negotiations aimed at reducing the scope of the Non-Core Activities order backlog.
Consolidated Group
Consolidated Group guidance reflects the sum of the guidance for the three business segments. Guidance for 2023 is subject to uncertainty due to the global supply chain situation, potential recession and geopolitical turmoil.
Contacts:
Investor Relations
Jannick Lindegaard Denholt, +45 21 69 66 57, jli@flsmidth.com
Therese Möllevinge, +45 41 37 16 38, tmo@flsmidth.com
Mikkel Johansen, +45 23 30 29 50, mjoh@flsmidth.com
Media Relations
Rasmus Windfeld, +45 40 44 60 60, rwin@flsmidth.com
About FLSmidth
FLSmidth provides sustainable productivity to the global mining and cement industries. We deliver market-leading technology, products and service solutions that enable our customers to improve performance, drive down costs and reduce environmental impact. MissionZero is our sustainability ambition towards zero emissions in mining and cement by 2030. FLSmidth works within fully validated Science-Based Targets, our commitment to keep global warming below 1.5°C and to becoming carbon neutral in our own operations by 2030. www.flsmidth.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Adevinta (ASA) publishes its 2023 Annual Report26.4.2024 08:30:00 CEST | Press release
Oslo, 26 April 2024 – Adevinta ASA today released its 2023 Annual Report, available here. A printed copy may be obtained free of charge upon written request to: ir@adevinta.com. Reflecting on 2023, Antoine Jouteau, CEO, said: “Over the past year, we have made significant progress on redesigning our operating model, verticalising our organisation in line with our Growing At Scale strategy and successfully completing our portfolio optimisation. We have achieved strong financial and operational performance in 2023 and continued to deliver against our targets, despite the tough macroeconomic environment. Following the divestment of our Hungarian classifieds business, our portfolio is now centred around our core European markets of France, Germany, Spain, Italy and Benelux, complemented by Canada and our joint ventures. We are delivering significant growth in our Mobility, Re-Commerce and Real Estate & Emerging verticals, substantiating our focus in these areas. By putting technology and pr
PCI Biotech Holding ASA - Annual Report 202326.4.2024 08:08:19 CEST | Press release
Oslo, Norway, April 26, 2024. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, rs@pcibiotech.no, Mobile: +47 940 05 757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments 2023 Annual Report PCI Biotech Holding ASApcibiotechholdingasa-2023-12-31-en
Delårsrapport för januari – mars 202426.4.2024 08:00:00 CEST | Pressemelding
STOCKHOLM – den 26 april 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2024. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Det har varit en stark inledning på 2024 där utvecklingen inom respektive portföljbolag löper enligt plan. Trots att vi haft ett motigt marknadsklimat har våra portföljbolag outtröttligt fortsatt driva utvecklingen av framtidens behandlingar vidare för att de så snabbt som möjligt ska komma patienterna till gagn. Vi ser fram emot tilltagande medvind och fler framsteg under året”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget OssDsign rapporterade positiva data från den kliniska studien TOP FUSION. Top-line-resultaten, som granskats av oberoende radiologer, visar en fusionsgrad på 93 procent 12 månader efter operation med det nya nanosyntetiska bengraftet OssDsign Catalyst (januari 2024).Portföljbolaget AnaCardio erhöll SEK 50 mil
Interim Report - January-March 202426.4.2024 08:00:00 CEST | Press release
STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The full report is available on the Company's website. “2024 has begun strongly with development within the respective portfolio companies proceeding according to plan. The adverse market climate we have previously experienced notwithstanding, our portfolio companies have continued tirelessly to advance the development of tomorrow’s treatments in order that patients can reap the benefits as quickly as possible. We look forward to an increasing tailwind and further progress during the year”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the first quarter The portfolio company OssDsign reported positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst
Solvay publishes notice of 2024 Annual General Meeting26.4.2024 08:00:00 CEST | Press release
Brussels, April 26, 2024, 8:00am CEST - regulated information Solvay today published materials for its next Ordinary General Shareholders’ Meeting, which will be held on Tuesday May 28, 2024 at the Event Lounge Conference Center, Boulevard Général Wahis 16/F, 1030 Brussels, at 10.30 am CEST. All documents relating to this meeting are now available on www.solvay.com. Shareholders will be asked to vote on a number of resolutions, among others: the approval of the financial statements for the financial year 2023; the approval of a total gross dividend of €2.43 per share; the approval of the revised directors’ remuneration; the renewal of the mandate, for a four-year period, of Ms Aude Thibaut de Maisières, as Director of the company; the appointment of EY regarding the assurance of sustainability information imposed by the EU Directive on sustainability reporting (Corporate Sustainability Reporting Directive); the approval of the change of control provision relating to the issuance of eur